Compare · ABEO vs TSHA
ABEO vs TSHA
Side-by-side comparison of Abeona Therapeutics Inc. (ABEO) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABEO focuses on Biotechnology: Pharmaceutical Preparations, while TSHA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TSHA is the larger of the two at $1.58B, about 5.1x ABEO ($311.2M).
- Over the past year, ABEO is down 16.5% and TSHA is up 96.4% - TSHA leads by 112.9 points.
- TSHA has been more active in the news (6 items in the past 4 weeks vs 5 for ABEO).
- TSHA has more recent analyst coverage (17 ratings vs 7 for ABEO).
- Company
- Abeona Therapeutics Inc.
- Taysha Gene Therapies Inc.
- Price
- $5.46-6.02%
- $5.50-6.78%
- Market cap
- $311.2M
- $1.58B
- 1M return
- -9.08%
- -21.32%
- 1Y return
- -16.51%
- +96.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 6
- Recent ratings
- 7
- 17
Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest ABEO
- Abeona Therapeutics Inc. filed SEC Form 8-K: Other Events
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Alvino Mark gifted 500 shares, decreasing direct ownership by 0.64% to 77,065 units (SEC Form 4)
- Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
- Director Alvino Mark sold $35,463 worth of shares (6,500 units at $5.46), decreasing direct ownership by 8% to 77,565 units (SEC Form 4)
- Director Crombez Eric sold $144,636 worth of shares (26,143 units at $5.53) as part of a pre-agreed trading plan, decreasing direct ownership by 41% to 37,313 units (SEC Form 4)
- SEC Form 10-Q filed by Abeona Therapeutics Inc.
- Abeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Chief Commercial Officer Vasanthavada Madhav sold $33,073 worth of shares (5,548 units at $5.96), decreasing direct ownership by 2% to 313,071 units (SEC Form 4) to satisfy withholding obligation
Latest TSHA
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Stalfort John A Iii was granted 21,335 shares, increasing direct ownership by 2% to 1,176,559 units (SEC Form 4)
- Director Sepp-Lorenzino Laura was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)
- Director Long Alison S was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)
- Director Donenberg Phillip B. was granted 21,335 shares, increasing direct ownership by 10% to 241,289 units (SEC Form 4)
- SEC Form 8-K filed by Taysha Gene Therapies Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- SEC Form 10-Q filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update